Ausblick

Kronenberg, Volker

doi:10.1007/978-3-531-19869-9_11

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following that, women experience several symptoms such as hot flush, mood swing, insomnia, vaginal dryness, mental confusion, stress incontinence, loss of libido, osteoporosis and cardiovascular diseases. [1][2][3][4][5] Although hormone replacement therapy is often used to overcome these conditions, there are increased concerns about its risks of vaginal bleeding, as well as breast and cervical cancer development. Hence, there has been continuous research for new oestrogenic agents for therapeutic purpose.…”

Section: Introductionmentioning

confidence: 99%

Oestrogenic activity of mimosine on MCF‐7 breast cancer cell line through the ERα‐mediated pathway

et al. 2018

View full text Add to dashboard Cite

Hormone replacement therapy has been a conventional treatment for postmenopausal symptoms in women. However, it has potential risks of breast and endometrial cancers. The aim of this study was to evaluate the oestrogenicity of a plant-based compound, mimosine, in MCF-7 cells by in silico model. Cell viability and proliferation, ERα-SRC1 coactivator activity and expression of specific ERα-dependent marker TFF1 and PGR genes were evaluated. Binding modes of 17β-oestradiol and mimosine at the ERα ligand binding domain were compared using docking and molecular dynamics simulation experiments followed by binding interaction free energy calculation with molecular mechanics/Poisson-Boltzmann surface area. Mimosine showed increased cellular viability (64,450 cells/ml) at 0.1 μM with significant cell proliferation (120.5%) compared to 17β-oestradiol (135.2%). ER antagonist tamoxifen significantly reduced proliferative activity mediated by mimosine (49.9%).Mimosine at 1 μM showed the highest ERα binding activity through increased SRC1 recruitment at 186.9%. It expressed TFF1 (11.1-fold at 0.1 μM) and PGR (13.9-fold at 0.01 μM) genes. ERα-mimosine binding energy was −49.9 kJ/mol, and it interacted with Thr347, Gly521 and His524 of ERα-LBD. The results suggested that mimosine has oestrogenic activity.

show abstract

Section: Introductionmentioning

confidence: 99%